Scrip | What Does 2023 Hold for Biopharma? Part 6: Artificial Intelligence
Feb 2023
Originally posted by Scrip on February 10, 2023.
Tony Crisman, Managing Director in Lincoln’s Healthcare Group, shares his predictions for artificial intelligence in the biopharma industry.
Summary
-
Lincoln International’s Tony Crisman reveals his outlook on artificial intelligence in the biopharma industry with Scrip.
- Sign up to receive Lincoln's perspectives
Contributor
Meet Professionals with Complementary Expertise

I am enthusiastic about creating sustainable growth and the highest value for our clients, and strive to leave a positive footprint beyond any successful M&A transaction.
Friedrich Bieselt
Managing Director | Management Board Member
Frankfurt
I enjoy leading clients and realizing their objectives, while structuring solutions to issues that are both intriguing and challenging.
Øyvind Bjordal
Managing Director | Head of Switzerland
Zurich
I am inspired by working with entrepreneurs and innovators who feel passionately about what they are creating.
William Bowmer
Managing Director
San FranciscoRelated Perspectives

Beauty Outlook: Optimism for an Attractive 2023
Many investors are eyeing the year ahead for the beauty and personal care industry as it is ripe for accelerated growth due to several factors. 2022 had a key focus… Read More

Aerospace and Defense: Factors Powering M&A Activity
Lincoln International was pleased to speak on the Reshaping the Supply Chain Landscape: M&A Trends panel at Aviation Week Network’s A&D Supply Chain conference. During the panel, industry experts revealed… Read More

Lincoln International’s Global Packaging Team Reports Strong 2022 and Continued Demand for Packaging in 2023
Packaging activity in 2022 was strong but experienced a continued cooling as the year finished. While the latter half of this year showed a decline in the total number of… Read More

U.S. Distribution M&A Continues in an Evolving Market
Macroeconomic uncertainty, particularly the combination of widespread price inflation (and the Federal Reserve’s response to it) and expectations for a downturn in 2023, have eroded investor confidence since mid-2022, driving… Read More